💸 The Tape

It's official. Massachusetts voters will decide in November whether to become the first state in American history to repeal marijuana legalization — and the measure qualified by the thinnest of margins.

The Elections Division of the Secretary of the Commonwealth's Office formally certified Thursday that the anti-cannabis initiative will appear on the November 3, 2026 ballot. Organizers needed 12,429 certified signatures in the second round of petitioning after lawmakers declined to act on the measure in May. They submitted 12,889 — and after disallowances for uncertified signatures and county overages, exactly 12,551 were allowed.

They cleared the bar by 122 signatures.

Let that sink in. The most consequential threat to state-level cannabis reform in a decade made the ballot with a margin of error smaller than the crowd at a dispensary grand opening. And now the fight begins in earnest.

What the Measure Would Do

If enacted, the initiative would repeal the laws allowing regulated commercial sales of recreational cannabis and home cultivation — while maintaining legal possession and preserving the medical marijuana system. In practical terms: adults could still legally hold cannabis, but every one of the state's licensed adult-use retailers would be forced to close, every adult-use cultivation facility would go dark, and consumers would be pushed back to the two channels that existed before 2016 — the medical program and the illicit market.

The campaign behind the measure, the Coalition for a Healthy Massachusetts, is largely bankrolled by SAM Action — the dark-money affiliate of Kevin Sabet's Smart Approaches to Marijuana, the same organization currently testifying against rescheduling at the DEA's ALJ hearing and suing the federal government in the D.C. Circuit. Massachusetts is the beachhead of a coordinated national rollback strategy, with a companion effort in Maine that missed its 2026 deadline but remains alive for 2027.

The Market They Want to Kill

The industry this initiative targets is not a fledgling experiment. It's one of the most mature, productive cannabis markets in the country.

Massachusetts voters approved legalization in 2016 with 54% support, and regulated sales launched in November 2018. Since then, the market has grown to more than 400 licensed adult-use retailers generating approximately $1.65 billion in annual sales, with cumulative sales surpassing $8 billion. Prices have fallen dramatically for consumers, product testing and age verification are universal, and the illicit market has steadily ceded ground to regulated channels.

The fiscal contribution is equally substantial. Between the state's 10.75% cannabis excise tax, the 6.25% sales tax, and local option taxes of up to 3%, Massachusetts has collected well over $2 billion in cumulative cannabis tax revenue since sales began — with annual collections now running in the range of $300 million or more. Notably, cannabis excise revenue in Massachusetts has exceeded alcohol excise revenue every year since 2021 — a milestone that made national headlines and remains one of the most cited data points in American cannabis policy.

That revenue funds public schools, transportation infrastructure, public health programs, and — through local host community agreements and taxes — the budgets of hundreds of municipalities across the commonwealth. The industry supports tens of thousands of jobs spanning cultivation, manufacturing, retail, security, testing, and professional services.

The operators with exposure include some of the largest names in cannabis: Curaleaf, Green Thumb Industries, Cresco Labs, Ascend Wellness, and TerrAscend, alongside hundreds of independent and social equity businesses that exist nowhere else. Repeal wouldn't just erase corporate revenue — it would wipe out the small businesses, equity licensees, and local entrepreneurs that Massachusetts' program was specifically designed to include.

A Campaign Built on Deception

The path to the ballot has been littered with controversy. Voters reported that petitioners used fake cover letters referencing unrelated measures on affordable housing and same-day voter registration. Legal cannabis supporters filed a formal complaint over fraudulent signature gathering; the State Ballot Law Commission rejected the challenge. Industry operators sued, arguing the measure improperly combined unrelated subjects and that the attorney general's summary was misleading; the Supreme Judicial Court ruled against them in June.

Then came the video. A signature gatherer — working both the Massachusetts and Maine campaigns — was recorded outside a retail store standing next to a sign reading "keep cannabis legal," telling voters that signing the petition would help protect legalization. "This is what we're fighting against right here. That's why we vote no," he told confused signers, arguing the measure needed to reach the ballot so it could be defeated — an argument that inverts reality, since the initiative failing to qualify would have preserved the status quo entirely.

The Coalition for a Healthy Massachusetts fired the canvasser, calling the conduct "wholly unacceptable." A SAM staffer declined to comment when reached by Marijuana Moment. But the pattern across two states, multiple complaints, and documented video is difficult to dismiss as one bad actor. The campaign qualified by 122 signatures — a margin narrow enough that the documented deception plausibly made the difference.

The Counter-Campaign

The good news: the defense is already organized. A coalition of Massachusetts marijuana business leaders, healthcare professionals, and advocates has formally launched a campaign to defeat the measure, and the underlying politics favor them. A University of New Hampshire poll earlier this year found just 20% of Massachusetts voters support repeal — meaning the initiative starts 30 points underwater in a state that approved legalization a decade ago and has watched the sky stubbornly refuse to fall.

But 20% support in July means nothing in November if the "no" side is complacent. The repeal campaign has demonstrated it will spend money and shade the truth. The counter-campaign's tasks are clear: define the measure honestly and early — this is a full repeal of legal sales, not a safety reform; mobilize the hundreds of thousands of adults who use the legal market; activate the municipalities whose budgets depend on host agreements and local taxes; and put the industry's employees — real people with real jobs — at the center of the message.

Every operator in the state should be funding this fight. Every MSO with Massachusetts exposure should treat it as a material business risk, because it is one. And the broader industry should understand what SAM understands: if repeal succeeds anywhere, the playbook goes everywhere — Maine in 2027, then Colorado, Oregon, and beyond.

The Bottom Line

Massachusetts built one of America's most successful cannabis markets: $8 billion in sales, $2 billion in taxes, 400 retailers, and cannabis revenue outpacing alcohol. In November, voters will be asked to burn it down and hand the market back to unlicensed dealers.

The polling says they won't. The 122-signature margin says the other side never stops working. Four months to election day. The first-ever legalization repeal vote in American history is officially on.

Complacency is the only way it passes. Don't let it.

Source: Marijuana Moment

📈 Dog Walkers

Texas Temp Check

The Texas hemp wars are officially back on — and this time, the battle lines are drawn against an expanding medical cannabis backdrop.

During a Senate Health and Human Services Committee hearing Tuesday, Republican Sen. Charles Perry announced he will re-file a total ban on hemp-derived THC products when the next legislative session convenes in January 2027. "The taxpayer is going to stop funding at a minimum next session," Perry declared — setting up another existential fight for the state's estimated $5.5 billion hemp market.

The playbook is familiar. Perry's Senate Bill 3 passed both chambers in 2025 before Governor Greg Abbott vetoed it at the session's end, opting instead for regulation over prohibition. Whether Abbott would veto a second attempt — with federal hemp restrictions now looming and Texas's medical program expanding — is the open question hanging over the entire industry.

Tuesday's testimony focused heavily on pediatric exposure data: the Texas Poison Center Network logged 10,515 THC exposure calls (with children five and under the largest group), one Baylor Scott & White pediatric hospital reported cannabis-related visits quadrupling from 348 in 2021 to over 900 last year, and a national study showed pediatric THC poisonings rising 400% between 2018 and 2023 — statistics that ban proponents are wielding effectively.

The market context makes the stakes even higher. Multi-state operators including Trulieve are actively building out Texas locations under the expanded Compassionate Use Program, creating a regulated medical alternative that didn't meaningfully exist during the last ban fight. Retailers like Austinite Cannabis Co. — where roughly 60% of revenue comes from THC products — warn that prohibition simply pushes consumers to illicit sources.

What's next: interim hearings continue through the fall, Perry files in January, and the collision between a $5.5 billion hemp industry, an expanding medical program, and a governor who's already vetoed one ban will define Texas cannabis policy in 2027.

🗞️ The News

📺 Trade To Black

States Keep Moving While Washington Waits | TTB Presented by Flowhub

• Virginia Cleanup Needed: Lawmakers are scrambling to address concerns that recent legislation may have unintentionally repealed certain marijuana penalties, creating interpretation questions just as the state finalizes its adult-use framework for 2027.

• North Carolina Divided: Governor Josh Stein and House Speaker Destin Hall remain at odds over cannabis legalization — another example of how state-level reform continues to hinge on individual leadership dynamics rather than public opinion.

• Wyoming Won't Follow: Attorney General Bridget Hill announced Wyoming will not automatically adopt any future federal rescheduling — a reminder that Schedule III doesn't force state-level change, and prohibition states retain full authority over their own cannabis laws.

• Consumer Skepticism: A new poll shows many cannabis consumers don't expect the Trump administration to complete rescheduling this year, despite the ongoing ALJ hearing — reflecting years of accumulated cynicism from a process that has repeatedly stalled and disappointed.